Therapeutic Evaluation of Kalonji ( Nigella Sativa ) in Dyslipidemia - a Randomized Control Trial

Rasheed, Abdur; Siddiqui, Mahmudur Rahman; Khan, Javed

doi:10.12816/0008181

Cited by 5 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In dietary habits, 27 (90 %) patients had mixed dietary habits and only 3(10%) patients were vegetarian, and present data is in agreement with the study conducted by Rasheed A et al inferring that fatty diet is highly responsible for dyslipidaemia 13 . (Table 1).…”

Section: Discussionsupporting

confidence: 92%

Therapeutic Evaluation of Unani Formulation in Dyslipidaemia:a Randomized Controlled Study

Mand¹,

Ahmad²,

Khalid³

et al. 2016

J Biol Sci Opin

View full text Add to dashboard Cite

Dyslipidaemia is a leading medical problem affecting overall health status of an individual. Deranged levels of lipid profile are responsible for atherosclerosis which ultimately leads to development of vascular diseases. If left untreated, it may result in various life threatening complications. Objective was to compare and evaluate the efficacy of test drug Qurs-e-Luk with control drug "Lipotab" in the management of Dyslipidaemia. It was a single blind, randomized, controlled, clinical trial. Thirty subjects of dyslipidaemia were selected and randomly assigned to test (20 patients) and control group (10 patients). Qurs-e-Luk and Lipotab were given to test and control groups in the form of powder (5 gm twice a day) and tablet (2 tablets per day) respectively for 60 days. All the patients of both groups were assessed on subjective and objective parameters at the baseline and after completion of trial, and the study outcome was analyzed using appropriate statistical tests. The test drug showed significant effect on few subjective and objective parameters in comparison to control drug without any significant side effects or toxicity. In test group, improvement in palpitation, fatigue and reduction in S. triglycerides and LDL was statistically significant (p < 0.05). The study infers that the comparative analyses of both drugs was not statistically significant; although improvement in subjective parameters was noted in both groups, and the effect on objective parameters was observed only in test group.

show abstract

Section: Discussionsupporting

confidence: 92%

Therapeutic Evaluation of Unani Formulation in Dyslipidaemia:a Randomized Controlled Study

Mand¹,

Ahmad²,

Khalid³

et al. 2016

J Biol Sci Opin

View full text Add to dashboard Cite

show abstract

“…The result revealed that test group significantly decreased the level of TC 213.1 ± 11.16 mg/dL, TGs 175.5 ± 23.43 mg/dL, and LDL 133.7 ± 9.32 mg/dL, respectively. Whereas HDL level was 45.1 ± 2.74 mg/dL slightly increased (Rasheed et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

LC‐MS based metabolite profiling, in‐vitro antioxidant and in‐vivo antihyperlipidemic activity of Nigella sativa extract

Shrivastava

Shrestha

Pokhrel

et al. 2023

eFood

View full text Add to dashboard Cite

The aim of this study was to identify the bioactive phytoconstituents present in the aqueous extract of Nigella sativa and also, to evaluate the antioxidant and antihyperlipidemic activity in Wistar rats. The LC‐MS/MS analysis was assessed for the determination of different bioactive compounds present in N. sativa extract. Total phenolic and flavonoid content were determined by using validated Folin‐Ciocalteu and Aluminum chloride colorimetric methods, respectively. The in‐vitro antioxidant and in‐vivo antihyperlipidemic activity in Wistar rats were also evaluated. Preliminary phytochemical screening of the extract showed the presence of alkaloids, flavonoids, phenols, glycosides, and amino acids in the aqueous extract. The bioactive compounds of the aqueous extract were identified through LC‐MS/MS analysis. The in‐vitro antioxidant activity of N. sativa showed the highest free radical scavenging capacity in DPPH, H2O2, and OH radical scavenging assays with IC50 values 11.916 ± 2.828, 30.294 ± 13.790, and 12.048 ± 2.828 µg/mL, respectively. Evaluation of antihyperlipidemic activity of extract in Wistar rats showed that a high dose (800 mg/kg) of extract significantly decreased total cholesterol (TC) 71.76 ± 6.91 mg/dL, TG 83.6 ± 8.09 mg/dL, low‐density lipoproteins (LDL‐c) 33.86 ± 6.05 mg/dL, very low‐density lipoproteins (VLDL‐c) 16.72 ± 1.61 mg/dL level in blood. However, the HDL‐C level was significantly improved (21.18 ± 1.80 mg/dL) as compared to HFD‐induced control rats (11.76 ± 1.14 mg/dL) after 28 days of treatment. Also, at the same dose, animal body weight was also decreased to 162.6 ± 16.40 g compared with control 184.4 ± 10.24 g. The aqueous extract of N. sativa was found to be an effective natural source of antioxidant and hypolipidemic agents. This activity was attributed to the presence of diverse bioactive compounds in it.

show abstract

“…26 Rasheed et al indicated that in subjects with dyslipidemia, 2 g per day NS powder for 60 days decreased TC and LDL with no changes in other parameters. 27 In both studies, there were no control groups and dietary intake and physical activity levels of the study subjects were also not evaluated.…”

Section: Discussionmentioning

confidence: 99%

Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial

et al. 2015

View full text Add to dashboard Cite

Obesity is typically associated with increased risk factors of cardiovascular diseases (CVDs). Therefore, a therapeutic approach that aims to control body weight and metabolic profile might be effective in preventing CVDs. We aimed to determine the effects of Nigella Sativa (NS) oil with a low-calorie diet on cardiometabolic risk factors in obese women. In this double-blind randomized controlled clinical trial, 90 obese women were recruited. Participants were females aged 25-50 years old with body mass index (BMI) between 30 and 35 kg m(-2). They were randomly assigned to receive a low-calorie diet with 3 g per day (1 g before each meal) NS oil or placebo for 8 weeks. Anthropometric indices, dietary intake and biochemical parameters were measured at the baseline and after the intervention. Eighty-four females completed the trial (intervention n = 43, placebo n = 41). Two groups were similar in the baseline characteristics. After the intervention, dietary intake was changed in both groups compared to the baseline, but the differences were not significant between the two groups. In the NS group, weight (-6.0 vs. -3.6%; p < 0.01) and waist circumference (-6.9 vs. -3.4%; p < 0.01) decreased significantly compared with the placebo group at the end of the trial. Comparison of biochemical parameters presented a significant decline in triglyceride (-14.0 vs. 1.4%; p = 0.02) and very low density lipoprotein (-14.0 vs. 7%; p < 0.01) levels in the NS group compared to the placebo group. NS oil concurrent with a low-calorie diet can reduce cardiometabolic risk factors in obese women. However, more clinical trials are needed to elucidate efficacy of NS as a complementary therapy in obese subjects.

show abstract

Therapeutic Evaluation of Kalonji ( Nigella Sativa ) in Dyslipidemia - a Randomized Control Trial

Cited by 5 publications

References 8 publications

Therapeutic Evaluation of Unani Formulation in Dyslipidaemia:a Randomized Controlled Study

Therapeutic Evaluation of Unani Formulation in Dyslipidaemia:a Randomized Controlled Study

LC‐MS based metabolite profiling, in‐vitro antioxidant and in‐vivo antihyperlipidemic activity of Nigella sativa extract

Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial

Contact Info

Product

Resources

About